虚拟生物等价性评估和溶解安全空间探索用于固定剂量甲胺-甘化片使用生理学基础生物制药建模
Chenshuang Zhao1, Chaozhuang Shen1, Yumeng Xiao1
1Department of Clinical Pharmacy and Pharmacy Administration, West China School of Pharmacy, Sichuan University, Chengdu 610064, China.
Pharmaceutics
|October 29, 2025
概括
基于生理学的生物制药建模 (PBBM) 成功评估了甲胺-甘胺固定剂量组合 (FDC) 的虚拟生物等价性 (VBE). 这种方法优化了溶解测试规范,以确保药物的质量和治疗等价性.
科学领域:
- 药物动力学和生物制药学
- 药物配方和开发 药物配方和开发
背景情况:
- 固定剂量组合 (FDC) 对于管理高血压和糖尿病等慢性疾病至关重要.
- 通用FDC需要对每个活性药物成分 (API) 的药物等价性和生物等价性 (BE) 进行严格的评估.
- 基于生理学的生物制药建模 (PBBM) 将体外特性与体内药理学联系起来,评估配方对全身暴露的影响.
研究的目的:
- 为甲胺-甘化物FDC开发一个 PBBM.
- 调查该FDC的临床相关质量规范.
- 评估虚拟生物等价性 (VBE) 并定义BE保证溶解参数.
主要方法:
- 使用PK-Sim®软件 (版本11.3) 来构建甲胺-甘化物FDC的 PBBM.
- 进行灵敏度分析以确定关键参数和设计虚拟群体.
- 进行了VBE分析,比较了参考和测试配方,并探索了溶解特性.
主要成果:
- 开发的 PBBM 准确地捕获了药物产品的体内行为.
- 敏感性分析显示,胃肠道 (GI) 的pH值和传输时间是影响全身暴露的关键因素.
- VBE分析证实了配方之间的生物等价性,为FDC定义了溶解安全空间.
结论:
- PBBM系统地评估了甲胺-甘化物FDC的VBE.
- 建立了用于体外溶解测试的优化验收标准.
- 研究和定义了FDC临床相关的质量规范.
关键词:
这就是PK-Sim.固定剂量组合 (FDC) 是一种固定剂量组合.甘化的使用方法甲胺是一种甲胺.基于生理学的生物制药建模 (PBBM)安全空间安全空间空间.灵敏度分析是一种敏感度分析.虚拟生物等价性 (VBE) 是指更多相关视频
相关概念视频
Bioequivalence studies: Biowaivers
218
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
218
Drug Dissolution: Requirements and Profile Comparison
232
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
232
In Vitro Drug Dissolution: Compendial Testing Models I
221
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
221
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
146
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
146
In Vitro Drug Dissolution: Compendial Testing Models II
237
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
237
Bioavailability Study Design: Healthy Subjects Versus Patients
143
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
143


